CA3140767A1 - Benzo[h][1,6] naphtyridin-2(1h)-ones utilises en tant qu'inhibiteurs de bmx destines a etre utilises contre le cancer - Google Patents

Benzo[h][1,6] naphtyridin-2(1h)-ones utilises en tant qu'inhibiteurs de bmx destines a etre utilises contre le cancer Download PDF

Info

Publication number
CA3140767A1
CA3140767A1 CA3140767A CA3140767A CA3140767A1 CA 3140767 A1 CA3140767 A1 CA 3140767A1 CA 3140767 A CA3140767 A CA 3140767A CA 3140767 A CA3140767 A CA 3140767A CA 3140767 A1 CA3140767 A1 CA 3140767A1
Authority
CA
Canada
Prior art keywords
compound
group
formula
covalent bond
bmx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3140767A
Other languages
English (en)
Inventor
Joao Seixas
Goncalo Bernardes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto de Medicina Molecular Joao Lobo Antunes
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3140767A1 publication Critical patent/CA3140767A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé de formule (I), et son utilisation dans des méthodes de traitement comprenant le traitement du cancer. Le composé a la structure représentée ci-dessous où D est un groupe accepteur et -A-, -L-, R<sup>7</sup> sont tels qu'exposés dans la demande : Formule (1a). La présente invention concerne également un composé de formule (II), et son utilisation dans des méthodes de traitement comprenant le traitement du cancer. Le composé a la structure représentée ci-dessous où D est un groupe accepteur et -A-, -L-, R6 sont tels qu'exposés dans la formule (1b) de la demande.
CA3140767A 2019-06-07 2020-06-05 Benzo[h][1,6] naphtyridin-2(1h)-ones utilises en tant qu'inhibiteurs de bmx destines a etre utilises contre le cancer Pending CA3140767A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1908171.0A GB201908171D0 (en) 2019-06-07 2019-06-07 Compounds
GB1908171.0 2019-06-07
PCT/EP2020/065730 WO2020245430A1 (fr) 2019-06-07 2020-06-05 Benzo[h][1,6] naphtyridin-2(1h)-ones utilisés en tant qu'inhibiteurs de bmx destinés à être utilisés contre le cancer

Publications (1)

Publication Number Publication Date
CA3140767A1 true CA3140767A1 (fr) 2020-12-10

Family

ID=67386187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3140767A Pending CA3140767A1 (fr) 2019-06-07 2020-06-05 Benzo[h][1,6] naphtyridin-2(1h)-ones utilises en tant qu'inhibiteurs de bmx destines a etre utilises contre le cancer

Country Status (6)

Country Link
EP (1) EP3980126A1 (fr)
CN (1) CN114206867A (fr)
AU (1) AU2020288706A1 (fr)
CA (1) CA3140767A1 (fr)
GB (1) GB201908171D0 (fr)
WO (1) WO2020245430A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115124524A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 三环类衍生物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013154778A1 (fr) 2012-04-11 2013-10-17 Dana-Farber Cancer Institute, Inc. Inhibiteurs ciblant l'hôte du virus de la dengue et d'autres virus
WO2014063054A1 (fr) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations
CN104829610B (zh) * 2014-06-20 2017-03-15 中国科学院合肥物质科学研究院 一种新型布鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
AU2020288706A1 (en) 2022-01-06
WO2020245430A1 (fr) 2020-12-10
EP3980126A1 (fr) 2022-04-13
GB201908171D0 (en) 2019-07-24
CN114206867A (zh) 2022-03-18

Similar Documents

Publication Publication Date Title
JP7264642B2 (ja) エフェクターｔ細胞機能を増進するための、セレブロンを標的とする小分子
US9820976B2 (en) 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
KR20220142999A (ko) 바이러스 증식 저해 작용을 갖는 트라이아진 유도체 및 그들을 함유하는 의약 조성물
Sampson et al. The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1 R, 2 S)-2-(3-((E)-4-(((cis)-2, 6-Dimethylmorpholino) methyl) styryl)-1 H-indazol-6-yl)-5′-methoxyspiro [cyclopropane-1, 3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent
KR102475498B1 (ko) 리신 특이적 데메틸라아제-1의 억제제
DK2855448T3 (en) 5 - [[4 - [[MORPHOLIN-2-YL] METHYLAMINO] -5- (TRIFLUORMETHYL) -2-PYRIDYL] AMINO] PYRAZINE-2-CARBONITRIL AND THERAPEUTIC APPLICATIONS THEREOF
JP2018184438A (ja) Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物
KR20150135374A (ko) 바이러스 감염증의 치료를 위한 거대환식 데아자-퓨리논
JP6307088B2 (ja) キナゾリノンおよびイソキノリノン誘導体
Xi et al. Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking
Mai et al. 5-Alkyl-2-alkylamino-6-(2, 6-difluorophenylalkyl)-3, 4-dihydropyrimidin-4 (3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family
Cappelli et al. Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. Development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties
WO2011127406A2 (fr) Acridines en tant qu&#39;inhibiteurs des kinases haspine et dyrk
CA3140767A1 (fr) Benzo[h][1,6] naphtyridin-2(1h)-ones utilises en tant qu&#39;inhibiteurs de bmx destines a etre utilises contre le cancer
Wang et al. Discovery of a new class of valosine containing protein (VCP/P97) inhibitors for the treatment of non-small cell lung cancer
ES2360014T3 (es) Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol-3-il)-fenoxi)metil)quinolina.
Zampieri et al. Discovery of new potent dual sigma receptor/GluN2b ligands with antioxidant property as neuroprotective agents
US9212144B2 (en) 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
Xu et al. Design and synthesis of Grp94 selective inhibitors based on Phe199 induced fit mechanism and their anti-inflammatory effects
Choudhary et al. Simple monocyclic pyrimidine analogs as microtubule targeting agents binding to the colchicine site
Park et al. Kinase and GPCR polypharmacological approach for the identification of efficient anticancer medicines
Johnson et al. Synthesis, kinetics and cellular studies of new phenothiazine analogs as potent human-TLK inhibitors
Gao et al. Discovery of novel 5-fluoro-N 2, N 4-diphenylpyrimidine-2, 4-diamines as potent inhibitors against CDK2 and CDK9
US9663468B2 (en) 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
Rosen et al. Discovery of potent cholecystokinin-2 receptor antagonists: Elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis